
Reducing a major cost burden of therapeutic cell manufacturing by selectivelyremoving toxic culture byproducts to allow recycling of mediaAward last edited on: 2/2/2022
Sponsored Program
STTRAwarding Agency
NIH : NIGMSTotal Award Amount
$224,453Award Phase
1Solicitation Topic Code
859Principal Investigator
Emily HopewellCompany Information
Ossium Health Inc
1121 Howard Sttreet
San Francisco, CA 94103
San Francisco, CA 94103
(415) 513-5535 |
info@ossiumhealth.com |
www.ossiumhealth.com |
Research Institution
----------
Phase I
Contract Number: 1R41GM140787-01A1Start Date: 9/20/2021 Completed: 7/19/2022
Phase I year
2021Phase I Amount
$224,453Project Terms:
Adsorption ; Amino Acids ; aminoacid ; Ammonia ; Ammonium ; Automobile Driving ; driving ; Back ; Dorsum ; Blood Platelets ; Marrow platelet ; Platelets ; Thrombocytes ; bone ; Bone Marrow ; Bone Marrow Reticuloendothelial System ; Buffers ; Carbon ; Cell Culture Techniques ; cell culture ; cell growth ; Cellular Expansion ; Cellular Growth ; Cells ; Cell Body ; Cellulose ; Polyanhydroglucuronic Acid ; alpha-Cellulose ; Chemistry ; Clinical Medicine ; Clinical Medical Sciences ; Culture Media ; growth media ; Animal Disease Models ; Economics ; Equilibrium ; balance ; balance function ; Face ; faces ; facial ; Filtration ; Filtration Fractionation ; Future ; gene therapy ; DNA Therapy ; Gene Transfer Clinical ; Genetic Intervention ; gene-based therapy ; genetic therapy ; genomic therapy ; Goals ; Growth ; Generalized Growth ; Tissue Growth ; ontogeny ; Health ; Human ; Modern Man ; Immunotherapy ; Immune mediated therapy ; Immunologically Directed Therapy ; immune therapeutic approach ; immune therapeutic interventions ; immune therapeutic regimens ; immune therapeutic strategy ; immune therapy ; immune-based therapies ; immune-based treatments ; immuno therapy ; Indiana ; Kinetics ; Methods ; Organ Donor ; Production ; Plant Resins ; resin ; Resources ; Research Resources ; medical schools ; medical college ; school of medicine ; Sugar Acids ; Technology ; Testing ; Tissue Donors ; Universities ; Waste Products ; Work ; Lactic acid ; cytokine ; Measures ; Porosity ; base ; sensor ; Area ; Surface ; Clinical ; Penetration ; Serum ; Blood Serum ; wasting ; Licensing ; Recycling ; Collaborations ; cell mediated therapies ; cell-based therapeutic ; cell-based therapy ; cellular therapy ; Cell Therapy ; Therapeutic ; Metabolic ; programs ; Frequencies ; Complex ; Source ; cell type ; System ; Performance ; success ; Nutrient ; economic impact ; Devices ; Abscission ; Extirpation ; Removal ; Surgical Removal ; resection ; Excision ; Vertebral Bone ; Modeling ; cell bank ; Regenerative Medicine ; Mesenchymal Progenitor Cell ; Mesenchymal progenitor ; Mesenchymal Stem Cells ; Address ; Dose ; Data ; Supplementation ; Allogenic ; Characteristics ; Development ; developmental ; cost ; design ; designing ; cost effective ; Consumption ; prototype ; large scale production ; efficacy testing ; manufacturing scale-up ; Complex Analysis ; Growth Factor ; Growth Agents ; Growth Substances ; Proteins Growth Factors ; preservation ;
Phase II
Contract Number: ----------Start Date: 00/00/00 Completed: 00/00/00